AIHTA - Publications - Search - Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer

Rothschedl, E. and Wolf, S. (2022): Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer. Oncology Fact Sheet Nr. 104.

[thumbnail of Oncology Fact Sheet Nr.104.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
98kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WP Gynaecology > WP 800-910 Breast
Language:English
Series Name:Oncology Fact Sheet Nr. 104
Deposited on:26 Jul 2022 14:56
Last Modified:26 Jul 2022 14:56

Repository Staff Only: item control page